BOSTON, July 17, 2024 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as 'natural hotspots,' today announced it will present initial clinical data, with a focus on safety, exposure, and pharmacodynamic measures, from the monotherapy dose-escalation portion of the Phase 1 study of HST-1011, an oral, selective inhibitor of Casitas B-lineage lymphoma proto-oncogene (CBL-B), in a Proffered Paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024, taking place September 13-17, 2024, in Barcelona, Spain..

波士顿，2024年7月17日/PRNewswire/--HotSpot Therapeutics，Inc.，一家生物技术公司，率先发现和开发针对蛋白质调节位点的口服小分子变构疗法，称为“自然热点”，今天宣布，它将在2024年9月13日至17日于2024年举行的欧洲医学肿瘤学会（ESMO）2024年大会上发表的一篇论文中，提供初步临床数据，重点是安全性，暴露性和药效学措施，该数据来自HST-1011（一种Casitas B谱系淋巴瘤原癌基因（CBL-B）的口服选择性抑制剂）第一阶段研究的单一疗法剂量递增部分。西班牙巴塞罗那。。

Presentation details are as follows:

演示详细信息如下：

Title: First-in-Human (FIH) Phase 1 Data of HST-1011, an Oral CBL-B Inhibitor, in Patients with Advanced Solid TumorsSession Name: Proffered Paper session: Investigational immunotherapySession Date and Time: Fri., Sep. 13, 2024, 16:00-17:30 CESTPresentation Time: 16:50-17:00 CESTLocation: Burgos Auditorium – Hall 5, Fira Barcelona Gran ViaPresentation Number: 991O.

标题：口服CBL-B抑制剂HST-1011在晚期实体瘤患者中的首次人体（FIH）1期数据会议名称：提交的论文会议：研究性免疫治疗会议日期和时间：2024年9月13日，星期五，16:00-17:30 CEST会议时间：16:50-17:00 CEST会议地点：布尔戈斯礼堂-5号大厅，Fira巴塞罗那格兰维亚会议编号：991O。

About HotSpot Therapeutics, Inc.HotSpot Therapeutics, Inc. is a clinical-stage biotechnology company that is pioneering a new class of allosteric drugs that target certain naturally occurring pockets on proteins called 'natural hotspots.' These pockets are decisive in controlling a protein's cellular function and have significant potential for new drug discovery by enabling the systematic design of potent and selective small molecules with novel pharmacology.

关于HotSpot Therapeutics，Inc.HotSpot Therapeutics，Inc.是一家临床阶段的生物技术公司，它开创了一类新的变构药物，针对蛋白质上某些天然存在的口袋，称为“天然热点”这些口袋在控制蛋白质的细胞功能方面起着决定性的作用，并且通过系统设计具有新药理学的有效和选择性小分子，具有发现新药的巨大潜力。

The Company's proprietary Smart Allostery™ platform combines computational approaches and AI-driven data mining of large and diverse data sets to uncover hotspots with tailored pharmacology toolkits and bespoke chemistry to drive the rapid discovery of novel hotspot-targeted small molecules. Leveraging this approach, HotSpot is building a broad pipeline of novel allosteric therapies for the treatment of cancer and autoimmune diseases.

该公司专有的Smart Allostery™平台将计算方法和人工智能驱动的大型多样化数据集数据挖掘相结合，通过定制的药理学工具包和定制化学来发现热点，以推动快速发现新的热点靶向小分子。利用这种方法，HotSpot正在建立一个广泛的新型变构疗法管道，用于治疗癌症和自身免疫性疾病。

To learn more, visit www.hotspotthera.com..

To learn more, visit www.hotspotthera.com..

Investor & Media Contact:Natalie Wildenradtnwildenradt@hotspotthera.com

投资者、媒体联系人：NatalieWildenradtnwildenradt@hotspotthera.com

SOURCE HotSpot Therapeutics

源热点疗法